Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

Song, Jehun; Kang, Sung-Hwa; Choi, Seung Won; Seo, Kwang Won; Lee, Soo Kon; So, Min Wook; Lim, Doo-Ho

doi:10.1007/s00296-020-04584-7

Cited by 29 publications

(27 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RA is a risk factor for serious infections that contribute to high overall morbidity and mortality compared to the general population. The high susceptibility of RA patients to infections can be explained by several various endogenous and exogenous risk factors including (1) immune system imbalance caused by the disease itself, (2) the presence of comorbidities with immune de ciencies, and/or (3) the use of immunesuppressants such as the DMARDs [23,24]. Previous studies have reported that RA is associated with the risk of respiratory infections and respective complications, including viral diseases such as in uenza [25,26].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of hydroxychloroquine against SARS-CoV-2 infection in rheumatoid arthritis patients

Küçükakkaş

Aydın

2020

Preprint

View full text Add to dashboard Cite

INTRODUCTION: The effectiveness of hydroxychloroquine in SARS-CoV-2 prophylaxis and treatment is still controversial. In this study, our aim is to investigate the potential effects of hydroxychloroquine therapy on patients with diagnosed with rheumatoid arthritis and a confirmed SARS-CoV-2 infection.METHOD: We included patients who were followed up with a diagnosis of rheumatoid arthritis and whose SARS-CoV-2 infection was confirmed. The patients were divided into two groups as those who previously used hydroxychloroquine and those who did not, and were compared in terms of clinical and laboratory data.RESULTS: Our study included 17 patients with adequate data (2 males, 15 females). The mean age of the patients was 57.2 ± 11.6 years. 7 (41.2%) patients were receiving hydroxychloroquine regularly for the last 6 months. When the effect of hydroxychloroquine on clinical and laboratory parameters of patients was examined, there was no significant difference between the groups of patients using and not using hydroxychloroquine. The patients using and not using hydroxychloroquine were compared for the presence of typical SARS-CoV-2 infection findings on computed tomography images, admission to the hospital and intensive care. No significant differences were observed between these two groups.CONCLUSIONS: Many studies on the effectiveness of hydroxychloroquine use in SARS-CoV-2 infection are still ongoing. Due to its importance in rheumatology practice, it is very important to clarify the position of hydroxychloroquine in SARS-CoV-2 therapy. Our findings suggest that having previously used hydroxychloroquine does not have any negative or positive effect on the infection.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Thereby, it halts the transcription of proin ammatory genes and reduces the likelihood of a cytokine storm (type-I interferons, IL-1, and TNF-alpha) [9]. Furthermore, it can inhibit the glycolysis of angiotensin-converting enzyme-2 receptor (ACE2R), which is the receptor used by SARS-CoV-2 to enter cells [10,11].…”

Section: Introductionmentioning

confidence: 99%

The effect of hydroxychloroquine against SARS-CoV-2 infection in rheumatoid arthritis patients

Küçükakkaş

Aydın

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The infection continues to spread rapidly worldwide and causes many people deaths. Patients with rheumatic disease can become easily and severely infected with SARS-CoV-2 because their immune system is suppressed [1]. Patients with rheumatic diseases use many immunosuppressants such as disease-modifying antirheumatic drugs.…”

Section: Dear Editormentioning

confidence: 99%

“…Tocilizumab is used for patients with severe SARS-CoV-2 infection [2]. Steroids use is not recommended during SARS-CoV-2 infection since the drugs may increase the tendency to pneumonia [1].…”

Section: Dear Editormentioning

confidence: 99%

See 1 more Smart Citation

Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)

Cüre¹,

Küçük

Cüre³

2020

Rheumatol Int

View full text Add to dashboard Cite

Implications of COVID-19 in pediatric rheumatology

Batu

Özen

2020

Rheumatol Int

View full text Add to dashboard Cite

(coronavirus disease 2019) pandemic caused by SARS-CoV-2, is a global public health issue threatening millions of lives worldwide. Although the infection is mild in most of the affected individuals, it may cause severe clinical manifestations such as acute respiratory distress syndrome or cytokine storm leading to death. Children are affected less, and most experience a milder disease. As rheumatologists, we deal with the uncontrolled response of the immune system, and most of the drugs we use are either immune modulators or immunosuppressants. Thus, the rheumatologists participate in the multidisciplinary management of COVID-19 patients. On the other hand, our patients with rheumatic diseases constitute a vulnerable group in this pandemic. In this review, a systematic literature search was conducted utilizing MEDLINE/ PubMed and Scopus databases, and 231 COVID-19 patients with rheumatic diseases have been identified. Only one of these patients was a child. Among these, 9 (3.9%) died due to COVID-19. In light of the current data, the aspects of COVID-19 resembling rheumatic diseases, the possible reasons for why children are affected less severely, the hypothetic role of available vaccines in preventing COVID-19, the unique position of patients with rheumatic diseases in this pandemic, and the use of anti-rheumatic drugs in COVID-19 treatment are discussed.

show abstract

Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

Cited by 29 publications

References 20 publications

The effect of hydroxychloroquine against SARS-CoV-2 infection in rheumatoid arthritis patients

The effect of hydroxychloroquine against SARS-CoV-2 infection in rheumatoid arthritis patients

Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)

Implications of COVID-19 in pediatric rheumatology

Contact Info

Product

Resources

About